CN100415235C - Medicinal composition containing an HMG-CoA reductase inhibitor - Google Patents
Medicinal composition containing an HMG-CoA reductase inhibitor Download PDFInfo
- Publication number
- CN100415235C CN100415235C CNB038237059A CN03823705A CN100415235C CN 100415235 C CN100415235 C CN 100415235C CN B038237059 A CNB038237059 A CN B038237059A CN 03823705 A CN03823705 A CN 03823705A CN 100415235 C CN100415235 C CN 100415235C
- Authority
- CN
- China
- Prior art keywords
- hmg
- reductase inhibitor
- coa reductase
- blood vessel
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 59
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims description 73
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 187
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 235000019157 thiamine Nutrition 0.000 claims abstract description 15
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003495 thiamine Drugs 0.000 claims abstract description 14
- 239000011721 thiamine Substances 0.000 claims abstract description 14
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000004204 blood vessel Anatomy 0.000 claims description 63
- 210000003038 endothelium Anatomy 0.000 claims description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 52
- 150000003544 thiamines Chemical class 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 31
- 230000036765 blood level Effects 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 19
- 229960002855 simvastatin Drugs 0.000 claims description 19
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 19
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 17
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 17
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 14
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 14
- 229960005370 atorvastatin Drugs 0.000 claims description 14
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 10
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims description 10
- 229960002873 benfotiamine Drugs 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 7
- 230000017531 blood circulation Effects 0.000 claims description 7
- 229960002965 pravastatin Drugs 0.000 claims description 7
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000002485 urinary effect Effects 0.000 claims description 7
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 6
- 229960003765 fluvastatin Drugs 0.000 claims description 6
- 229960004844 lovastatin Drugs 0.000 claims description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 6
- 229960002797 pitavastatin Drugs 0.000 claims description 6
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 6
- 229960000672 rosuvastatin Drugs 0.000 claims description 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 claims description 4
- 229950006836 fursultiamine Drugs 0.000 claims description 4
- LLJDJQYGZBQFIF-FLIBITNWSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(1z)-1-(2-oxo-1,3-oxathian-4-ylidene)ethyl]formamide Chemical compound C\1COC(=O)SC/1=C(/C)N(C=O)CC1=CN=C(C)N=C1N LLJDJQYGZBQFIF-FLIBITNWSA-N 0.000 claims description 4
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 claims description 4
- VJTXQHYNRDGLON-LTGZKZEYSA-N octotiamine Chemical compound COC(=O)CCCCC(SC(C)=O)CCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N VJTXQHYNRDGLON-LTGZKZEYSA-N 0.000 claims description 4
- 229950011324 octotiamine Drugs 0.000 claims description 4
- 229950007142 prosultiamine Drugs 0.000 claims description 4
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 claims description 4
- IWXAZSAGYJHXPX-BCEWYCLDSA-N Bisbentiamine Chemical compound C=1C=CC=CC=1C(=O)OCC/C(SS\C(CCOC(=O)C=1C=CC=CC=1)=C(/C)N(CC=1C(=NC(C)=NC=1)N)C=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N IWXAZSAGYJHXPX-BCEWYCLDSA-N 0.000 claims description 3
- 229950009892 bisbentiamine Drugs 0.000 claims description 3
- YBROOZNJUDHTGE-QINSGFPZSA-N cetotiamine Chemical compound CCOC(=O)OCC\C(SC(=O)OCC)=C(/C)N(C=O)CC1=CN=C(C)N=C1N YBROOZNJUDHTGE-QINSGFPZSA-N 0.000 claims description 3
- 229950007625 cetotiamine Drugs 0.000 claims description 3
- 229960003211 sulbutiamine Drugs 0.000 claims description 3
- 229940123934 Reductase inhibitor Drugs 0.000 claims 2
- 125000001990 thiamine group Chemical group 0.000 claims 1
- 230000002792 vascular Effects 0.000 abstract description 3
- 239000000890 drug combination Substances 0.000 abstract 3
- 230000003511 endothelial effect Effects 0.000 abstract 2
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 18
- 239000002775 capsule Substances 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 208000002815 pulmonary hypertension Diseases 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- -1 hydrofluoride Chemical class 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003836 peripheral circulation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 229960001770 atorvastatin calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000011262 co‐therapy Methods 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical class NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-SJBCKIPMSA-N 3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-SJBCKIPMSA-N 0.000 description 1
- FJLGEFLZQAZZCD-UHFFFAOYSA-N 7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid Chemical compound C12=CC=CC=C2N(C(C)C)C(C=CC(O)CC(O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229950002217 cycotiamine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- ZYZHMSJNPCYUTB-UHFFFAOYSA-N n-benzyl-1-phenylethanamine Chemical class C=1C=CC=CC=1C(C)NCC1=CC=CC=C1 ZYZHMSJNPCYUTB-UHFFFAOYSA-N 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a drug combination, which can promote the synthesization of vascular endothelial nitrogen oxide and / or maintain or increase the concentration of the vascular endothelial nitrogen oxide in blood, or a drug combination, which improves blood fat. The drug combination contains HMG-CoA reductase inhibitor and Gamma-oryzanol and / or thiamine.
Description
Technical field
The present invention relates to contain HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class pharmaceutical composition (be particularly related to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keep or improve the blood vessel endothelium nitrogen oxide blood level pharmaceutical composition or improve the pharmaceutical composition of blood fat).
Background technology
The saying that " people is and blood vessel ageing simultaneously " arranged all the time, but be judged as recently is to make the nitric oxide (NO) that is produced by blood vessel endothelium reduce with the growth at age, various diseases etc., promptly in the active reduction of integumentary pattern NO synzyme (eNOS) very dark relation is arranged.
It is reported that the dysfunction of blood vessel endothelium and arteriosclerotic morbidity progress has very dark relation, the minimizing of the NO that is produced by eNOS is its maximum reason.The NO that comes from blood vessel wall from vasodilation, suppress platelet aggregation, suppress that neutrophilic leukocyte adheres to endotheliocyte, suppresses the migration propagation of vascular smooth muscle cell, the aspects such as oxidation that suppress LDL show the arteriosclerosis effect (for example reference, angiology Vol.38 No.41998 p.215-216.)。
In animal experiment, make the sick deterioration of arteriosclerosis, so directly promote arteriosclerosis morbidity progress (for example reference, vascular medicine Vol.2 No.22001p.189.) owing to suppressing the synthetic of NO.
Even for the people, the NO that blood vessel endothelium produces has many-sided effect for vascular protection, and therefore in the treatment of cardiovascular disease, it is important keeping the treatment countermeasure of improving vascular endothelial function.As making the active medicine that improves of eNOS, the Ca antagonist of the known 1 receptor antagonist that statins, L-arginine, ACE inhibitor, Angiotensin II arranged, hormone, a part, in addition, the antioxidants such as vitamin C, vitamin E, probucol that promote the NO effect by the inactivation that prevents NO indirectly also are effectively (for example references, pharmacology and treatment Vol.29 No.10 2001 are p.716.).
Known in addition vitamin C can make the active raising of eNOS (for example reference, vitamin V ol.75No.2 2001 p.511.).
In addition, find the effect (for example reference and Chinese medicine pharmaceutical journal Vol.111994 are p.102.) that Radix Ginseng, the Radix Astragali, Radix Scutellariae have stimulates blood vessel NO to generate in the crude drug of formation Chinese herbal medicine.
NO synzyme (NOS) also is present in beyond the blood vessel endothelium, has important function in regulating systemic circulation.Generate the disease that reduces as confirmed NO, known have hypertension, hyperlipemia, arteriosclerosis, ischemic heart desease, heart failure, blood circulation diseasess such as thrombosis, asthma, chronic occlusion pneumonopathy, pulmonary hypertension, ARDS respiratory illnesses such as (adult respiratory distress syndromes), hepatopathy, liver cirrhosis, the gastrointestinal mucosa disease, hypertrophic pylorostenosis disease, chylopoietic diseases such as pancreatitis, cerebral ischemia, cerebral infarction, the cerebral circulation disease, cerebrovascular disease such as alzheimer disease, nephropathy, kidney diseases of urinary system such as sexual impotence, gynaecopathias such as gestosis, the infectious disease disease of immune system, diabetes, burn or other known drug NO generation minimizing disease (for example reference, the spy opens flat 10-338637 communique .).
Statins is the medicine that suppresses the HMG-CoA reductase in vivo specifically and competitively, reduces the blood cholesterol amount, and known also have as the above-mentioned active effect of raising eNOS.But, do not have report about γ-Hi-Z and the active effect of thiamine class raising eNOS, statins and γ-Hi-Z and/or thiamine class and usefulness passable promoted the synthetic of blood vessel endothelium nitrogen oxide synergistically and/or are kept or to improve the effect of blood level of blood vessel endothelium nitrogen oxide not known yet.
In addition, by γ-Hi-Z and/or thiamine class and usefulness, synergistically blood fat reducing also artificial known to.
Summary of the invention
The result of the inventor through the pharmacological action of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class and usefulness is attentively studied, discovery is by this and with the effect of synthesizing, keeping or improve the blood level of blood vessel endothelium nitrogen oxide and improve blood fat of promotion blood vessel endothelium nitrogen oxide, thereby finished the present invention.
The present invention relates to
(1) contains the pharmaceutical composition of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class.
Above-mentioned pharmaceutical composition is,
(2) according to the compositions described in (1), the HMG-CoA reductase inhibitor is to be selected from pravastatin (pravastatin), lovastatin (lovastatin), simvastatin (simvastatin), fluvastatin (fluvastatin), uprightly to cut down in his spit of fland (rivastatin), atorvastatin (atorvastatin), Pitavastatin (pitavastatin) and the Rosuvastatin (rosuvastatin) a kind or multiple
(3) according to the compositions described in (1), the HMG-CoA reductase inhibitor is to be selected from simvastatin or the atorvastatin a kind or multiple,
(4) according to any described compositions in (1) to (3), the thiamine class be selected from thiamine, cetotiamine (dicethiamine), neuvitan (octotiamine), commetamin (cycotiamine), vitaberin (bisibuthiamine), bisbentiamine (bisbenthiamine), fursultiamine (fursultiamine), prosultiamine (prosultiamine), benfotiamine (benfotiamine) and/or their salt a kind or 2 kinds or more than
(5) according to any described compositions in (1) to (3), the thiamine class is a benfotiamine,
(6) according to any described compositions in (1) to (5), the blood level that said composition is used to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keeps or improve the blood vessel endothelium nitrogen oxide,
(7) according to any described compositions in (1) to (5), said composition is used to improve blood fat,
(8) according to the compositions described in (7), the HMG-CoA reductase inhibitor is a simvastatin,
(9) according to any described compositions in (1) to (5), said composition is used to prevent or treat the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or the blood level reduction of blood vessel endothelium nitrogen oxide causes,
(10) according to any described compositions in (1) to (5), said composition is used for preventing or treats the disease that causes that the blood vessel endothelium nitric oxide synthetase activities reduces and/or reduce from the blood nitric oxide concentration of blood vessel endothelium,
(11) according to any described compositions in (1) to (5), said composition is to cause that in order to prevent or to treat by blood circulation diseases, cerebrovascular disease, kidney diseases of urinary system, diabetes or by medicine NO generates the disease that reduces,
(12) according to any described compositions in (1) to (5), said composition is to result from the high disease of serum lipid concentrations in order to prevent or to treat,
(13) according to the compositions described in (12), contain HMG-CoA reductase inhibitor and γ-Hi-Z as essential composition,
(14) according to any described compositions in (1) to (5), said composition is in order to prevent or treat hyperlipemia or arteriosclerosis.
Further, the invention provides:
(15) conjoint therapy of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, be by with HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same the time or with official hour administration respectively at interval, promote the blood level that synthesizes and/or keep or improve the blood vessel endothelium nitrogen oxide of blood vessel endothelium nitrogen oxide
(16) conjoint therapy of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class is by HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same the time or with official hour administration respectively at interval, are improved blood fat,
(17) the also usefulness of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, the blood level that it is used to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keeps or improve the blood vessel endothelium nitrogen oxide,
(18) the also usefulness of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, it is used to improve blood fat.
Further the invention provides:
(19) promote the synthetic of blood vessel endothelium nitrogen oxide and/or keep or improve the method for the blood level of blood vessel endothelium nitrogen oxide, when comprising HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same or with official hour administration respectively at interval,
(20) improve the method for blood fat, when comprising HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same or with official hour administration respectively at interval.
Preferable methods is in above-mentioned (19):
(21) according to the method described in (19), this method is used to prevent or treat the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or the reduction of blood vessel endothelium nitrogen oxide blood level causes,
(22) according to the method described in (19), this method is used to prevent or treat the disease that causes that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces,
(23) according to the method described in (19), this method is used to prevent or treats by blood circulation diseases, cerebrovascular disease, kidney diseases of urinary system, diabetes or by medicine cause that NO generates the disease that reduces,
Preferable methods is in above-mentioned (20):
(24) according to the method described in (20), this method is used to prevent or treat the disease that hyperlipidemia concentration causes,
(25) according to the method described in (20), this method is used for prevention or treatment hyperlipemia or arteriosclerosis.
The invention provides in addition:
(26) purposes of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, it is used to prepare the pharmaceutical composition that contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, is used to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keeps or improve the blood level of blood vessel endothelium nitrogen oxide
(27) purposes of HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, it is used to prepare the pharmaceutical composition that contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, is used to improve blood fat.
" HMG-CoA reductase inhibitor " as one of pharmaceutical composition composition of the present invention is the medicine that suppresses cholesterol biosynthesis rate-limiting enzyme HMG (3-hydroxy-3-methyl glutaryl)-CoA reductase specifically and competitively.Because blood cholesterol is reduced, be medicine originally as hyperlipemia.This HMG-CoA reductase inhibitor comprises all the natural materials from microorganism, by its deutero-semi-synthetic material, and complete synthesis chemical compound, for example can enumerate following statin compound: the spy opens (+)-(3R that is put down in writing in the clear 57-2240 communique (USP4346227), 5R)-3,5-dihydroxy-7-[(1S, 2S, 6S, 8S, 8aR)-the 6-hydroxy-2-methyl-8-[(S)-2-methylbutyryl oxygen base]-1,2,6,7,8,8a-six hydrogen-1-naphthyl] enanthic acid (being designated hereinafter simply as pravastatin), the spy opens (+)-(1S of record in the clear 57-163374 communique (USP4231938), 3R, 7S, 8S, 8aR)-1,2,3,7,8,8a-six hydrogen-3,7-dimethyl-8-[2-[(2R, 4R)-and tetrahydrochysene-4-hydroxyl-6-oxygen-2H-pyrans-2-yl] ethyl]-1-naphthyl (S)-2-Methyl Butyric Acid ester (being designated hereinafter simply as lovastatin), the spy opens (+)-(1S of record in the clear 56-122375 communique (USP4444784), 3R, 7S, 8S, 8aR)-1,2,3,7,8,8a-six hydrogen-3,7-dimethyl-8-[2-[(2R, 4R)-and tetrahydrochysene-4-hydroxyl-6-oxygen-2H-pyrans-2-yl] ethyl]-1-naphthyl 2,2-dimethyl butyrate acid esters (being designated hereinafter simply as simvastatin), (±) (3R* of record in the special clear 60-500015 communique of table (USP4739073), 5S*, 6E)-and 7-[3-(4-fluorophenyl)-1-(1-Methylethyl)-1H-indole-2-yl]-3,5-dihydroxy-6-heptenoic acid (being designated hereinafter simply as fluvastatin), (the 3R of record in the Te Kaiping 1-216974 communique (USP5006530), 5S, 6E)-7-[4-(4-fluorophenyl)-2,6-two-(1-Methylethyl)-5-methoxy pyridin-3-yl]-3,5-dihydroxy-6-heptenoic acid (be designated hereinafter simply as upright cut down him spit of fland), (the 3R of record in the Te Kaiping 3-58967 communique (USP5273995), 5S)-and 7-[2-(4-fluorophenyl)-5-(1-Methylethyl)-3-phenyl-4-phenyl amino carbonyl-1H-pyrroles-1-yl]-3,5-dihydroxy enanthic acid (being designated hereinafter simply as atorvastatin), (E)-3 of record in the Te Kaiping 1-279866 communique (USP5854259 and USP5856336), 5-dihydroxy-7-[4 '-(4 "-fluorophenyl)-2 '-cyclopropyl-quinoline-3 '-yl]-6-heptenoic acid (being designated hereinafter simply as Pitavastatin) or spy open (+) of record in the flat 5-178841 communique (USP 5260440)-(3R; 5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonamido) pyridine-5-yl]-3,5-dihydroxy 6-(E)-heptenoic acid (being designated hereinafter simply as Rosuvastatin).In addition, also comprise, put down in writing disclosed other HMG-CoA reductase inhibitors in the communique of above-mentioned HMG-CoA reductase inhibitor as the HMG-CoA reductase inhibitor of pharmaceutical composition composition of the present invention.
Shown below is the planar structure formula of representative HMG-CoA reductase inhibitor.
The pravastatin lovastatin
The simvastatin fluvastatin
Upright his the spit of fland atorvastatin that cuts down
The Rosuvastatin Pitavastatin
In these HMG-CoA reductase inhibitors, preferred simvastatin and atorvastatin, more preferably simvastatin.
" γ-Hi-Z " is meant sterol that is extracted by Testa oryzae oil, rice germ oil or the chemical compound that is obtained through esterification by triterpene alcohol and ferulic acid, or their mixture.
Can enumerate thiamine, cetotiamine, neuvitan, commetamin, vitaberin, bisbentiamine, fursultiamine, prosultiamine or benfotiamine or its salt as " thiamine class ", preferred benfotiamine.
In the present invention, the form that above-mentioned each composition that contains can be an officinal salt, can enumerate as this salt:
Have the occasion of basic functionality at composition, for example can enumerate halogen acid salts such as hydrofluoride, hydrochlorate, hydrobromate, hydriodate; Inorganic acid salts such as nitrate, perchlorate, sulfate, phosphate; Rudimentary organic sulfonates such as mesylate, fluoroform sulphonate, ethyl sulfonate; Arylsulphonate such as benzene sulfonate, tosilate; Amino acid salts such as ornithine salt, glutamate, Glu; And carboxylate such as fumaric acid, succinic acid, citric acid, tartaric acid, oxalic acid, maleic acid,
Have the occasion of acidic functionality at composition, can enumerate alkali metal salts such as sodium salt, potassium salt, lithium salts, alkali salts such as calcium salt, magnesium salt, the slaine of aluminum salt, iron salt, zinc salt, mantoquita, nickel salt, cobalt salt etc.; Inorganic salts such as ammonium salt, t-octanylamine salt, the dibenzyl amine salt, alkylbenzyldimethylasaltsum saltsum, aminoglucose salt, the phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucosamine salt, guanidinesalt, the diethyl amine salt, triethylamine salt, dicyclohexyl amine salt, N, N '-dibenzyl ethylenediamine salt, the chloro procaine salt, procaine salt, diethanolamine salt, N-benzyl-1-phenylethylamine salt, piperazine salt, tetramethyl ammonium, amine salt such as organic salt such as three (methylol) aminomethane salt, for example when the time for pravastatin, preferred pravastatin sodium, for example when the time for atorvastatin, preferred atorvastatin hydrate of calcium.
In each composition that the present invention contains, the material that can form hydrate or solvate also can hydrate or solvate forms be contained in the pharmaceutical composition of the present invention.
So-called " various diseases " is meant among the present invention, the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces causes disease, or cause that the blood vessel endothelium nitric oxide synthetase activities reduces and/or the disease of blood vessel endothelium nitrogen oxide blood level reduction, comprise for example hypertension, hyperlipemia, arteriosclerosis, ischemic heart desease, heart failure, thrombosis, pulmonary hypertension, blood circulation diseasess such as restenosis (restenosis) or peripheral circulation disease, pulmonary hypertension, cerebral ischemia, cerebral infarction, cerebrovascular disease such as cerebral circulation disease or alzheimer disease, kidney such as nephropathy or sexual impotence diseases of urinary system, diabetes or cause the disease that NO generate to reduce by medicine.
In addition, no significant subjective symptoms in the initial stage of above-mentioned " various diseases ", and be not easy the oneself and discover, but as " various diseases " of the present invention related subjective symptoms, for example can enumerate that headache, dizzy, numbness or feeling of numbness, coolness of extremities, shoulder are ached, integumentary musculature atrophy or sexual impotence etc.Therefore, for the pharmaceutical composition of these subjective symptoms the application of the invention, the stage can be treated above-mentioned disease in the early stage.
So-called " improving blood fat " is meant that the lipid in the blood is reduced to the degree with clinical meaning among the present invention, promptly means triglyceride reducing, reduces in the blood LDL or reduces T-CHOL in the blood.
The specific embodiment
The HMG-CoA reductase inhibitor that contains in the present composition, for example, pravastatin, lovastatin, simvastatin, fluvastatin, upright his spit of fland of cutting down, atorvastatin, Pitavastatin or Rosuvastatin are opened clear 57-2240 communique (USP4346227) according to the spy, the spy opens clear 57-163374 communique (USP4231938), the spy opens clear 56-122375 communique (USP4444784), special table clear 60-500015 communique (USP4739073), Te Kaiping 1-216974 communique (USP5006530), Te Kaiping 3-58967 communique (USP5273995), the method that Te Kaiping 1-279866 communique (USP5854259 and USP5856336) or spy open record in the flat 5-178841 communique (USP5260440) can easily prepare.
γ-Hi-Z of the present invention can use commercially available γ-Hi-Z (for example, reason is ground PVC ミ Application (strain) system) or use the γ-Hi-Z for preparing by known method.
The thiamine class has been recorded outside the 14th edition Japanese Pharmacopoeia and Japanese Pharmacopoeia and in pharmaceuticals specification etc., can have been obtained easily.
" pharmaceutical composition that contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class " of the present invention contains HMG-CoA reductase inhibitor and γ-Hi-Z or thiamine class as essential composition, also can contain the additive that is useful on preparation as required, in to scope HMG-CoA reductase inhibitor and γ-Hi-Z or thiamine class and that have no adverse effects with effect, also can contain other composition.Preferably only contain HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class as effective ingredient, further contain the pharmaceutical composition of the additive that is useful on preparation.
Concrete dosage form as pharmaceutical composition of the present invention, for example enumerate tablet, granule (comprising powder), capsule, liquid preparation (comprising syrup) etc., in each dosage form, suitably use suitable additive, matrix material, the conventional method preparation that can be put down in writing according to Japanese Pharmacopoeia etc.
In above-mentioned each dosage form,, can use normally used various additive according to the difference of dosage form.
For example, when being tablet, can use lactose, crystalline cellulose etc. as excipient, aluminosilicate magnesium (magnesium alumiometasilicate) or magnesium oxide etc. are as stabilizing agent, hydroxypropyl celluloses etc. are as coating material, and magnesium stearate etc. are as lubricant
The occasion of granule and capsule can use lactose or castor sugar as excipient, and aluminosilicate magnesium or magnesium oxide etc. are as stabilizing agent, and corn starch etc. are as adsorbent, and hydroxypropyl cellulose etc. are as binding agent.
In above-mentioned each dosage form, also can add polyvinylpolypyrrolidone disintegrating agents such as (crospovidone) as required; Surfactants such as poly-Pyrusussuriensis fat; Adsorbents such as calcium silicates; Coloring agent such as iron sesquioxide, caramel; Stabilizing agents such as sodium benzoate; The pH regulator agent; Spice etc.
In the present invention, so-called " associating " be meant 2 kinds or 2 kinds or above effective ingredient simultaneously or with the official hour interval respectively to the method for human body administration.
When administration compositions of the present invention, each composition of compositions can be distinguished administration simultaneously or with official hour at interval.
Above-mentioned what is called " side by side " administration is meant, except that administration fully side by side, is also included within on the acceptable degree of pharmacology with official hour administration at interval.Its administering mode, so long as can be not particularly limited at the administering mode of roughly the same time administration, but preferred single compositions.
Above-mentioned what is called " is distinguished " administration at interval with official hour, so long as at different time administering mode of administration respectively, be not particularly limited, comprise for example first administration the 1st composition, then behind official hour, and the method for other compositions of administration.
In addition, the one-tenth subtotaling of the compositions of administration has the occasion more than 3 kinds or 3 kinds, so-called " distinguishing at interval simultaneously or with official hour " administration comprises: with its all administrations simultaneously method, with official hour at interval respectively the method for administration, with 2 kinds or 2 kinds or above medicine administration simultaneously after official hour at interval the remaining medicine of administration method or with 2 kinds or 2 kinds or above medicine through official hour at interval after the administration, the method for the remaining medicine of administration simultaneously etc.
The pharmaceutical composition that the present invention contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class has the synthetic effect of the blood vessel endothelium nitrogen oxide of promotion, keep or improve the effect of the blood level of blood vessel endothelium nitrogen oxide, with the effect that improves blood fat, therefore result from the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces as prevention or treatment, cause the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces, or result from the medicine of disease of hyperlipidemia concentration, for example, as prevention or treatment hypertension, hyperlipemia, arteriosclerosis, ischemic heart desease, heart failure, thrombosis, pulmonary hypertension, the blood circulation diseases of restenosis or peripheral circulation disease etc., pulmonary hypertension, cerebral ischemia, cerebral infarction, the cerebrovascular disease of cerebral circulation disease or alzheimer disease etc., the kidney diseases of urinary system of nephropathy or sexual impotence etc., diabetes or cause the medicine of the disease that NO generate to reduce by medicine.
The dosage of HMG-CoA reductase inhibitor is different because of the kind of HMG-CoA reductase inhibitor, dosage form etc. among the present invention, but normally every day 1mg to 200mg, preferably every day 5mg to 160mg.
The dosage of γ-Hi-Z among the present invention, normally every day 10mg to 1000mg, preferably every day 100mg to 600mg.
The dosage of thiamine class is different because of the kind of thiamine class, dosage form etc. among the present invention, but normally every day 0.5mg to 500mg, preferably every day 5mg to 200mg.
The weight % of the HMG-CoA reductase inhibitor that pharmaceutical composition of the present invention is contained when being solid preparation normally 0.005 to 3%, preferably 0.03 to 2%, for example when the time for simvastatin, normally 0.005 to 3%, preferably 0.03 to 2%, in addition when the time for atorvastatin, normally 0.01 to 5%, preferably 0.05 to 3%
When containing γ-Hi-Z, its content normally 0.5 to 90%, preferably 3 to 60%,
Contain the thiamine time-like, its content normally 0.2 to 40%, preferably 1 to 30%.
The content of the HMG-CoA reductase inhibitor that drug composition of the present invention is contained when being liquid preparation normally 0.005 to 5mg/mL, preferably 0.03 to 3mg/mL, for example the content of simvastatin is normally 0.005 to 5mg/mL, preferably 0.03 to 3mg/mL, the content of atorvastatin is normally 0.01 to 10mg/mL in addition, preferably 0.05 to 5mg/mL
When containing γ-Hi-Z, its content is normally 2 to 200mg/mL, and preferably 10 to 100mg/mL,
Contain the thiamine time-like, its content is normally 1 to 100mg/mL, and preferably 5 to 50mg/mL.
Implement best mode of the present invention
(embodiment)
Below, describe the present invention in detail by embodiment, but scope of the present invention is not limited in this.
Embodiment 1 tablet
(1) composition
(2) preparation method
Getting mentioned component and take by weighing its weight, is the standard fabrication tablet with Japanese Pharmacopoeia rules of preparations tablet item.
Embodiment 2 granules
(1) composition
(2) preparation method
Getting mentioned component and take by weighing its weight, is the standard fabrication granule with Japanese Pharmacopoeia rules of preparations granule item.
Embodiment 3 capsules
(1) composition
(2) preparation method
Get mentioned component and take by weighing its weight, be the standard fabrication granule with Japanese Pharmacopoeia rules of preparations granule item after, be filled into and prepare hard capsule in the capsule.
Embodiment 4 syrups
(1) composition
(2) preparation method
Get mentioned component and take by weighing its weight, be the standard fabrication syrup with Japanese Pharmacopoeia rules of preparations syrup item after, fill prepares syrup in the amber glass bottle.
(test example)
The nitric oxide levels in test example 1 blood and the evaluation test of lipid level
(1) measured matter
Use (strain) ケ system テ Star Network ラ ボ (Chemtech Labo. of company, Inc.) Zhi simvastatin and Atorvastatin calcium, use reason to grind PVC ミ Application (strain) (the Riken VitaminCo. of company, Ltd.) Zhi γ-Hi-Z, use three to be total to (strain) company (SankyoCo., Ltd.) Zhi benfotiamine in addition.
(2) animal
As experimental animal is male crust lattice (Beagle) dog from 5 monthly ages that Covance Research Products Inc. buys, raises the back through about 1 month quarantine and domestication and uses.
(3) store method of the preparation method of form of administration, preparation and preparation
Body weight with every experimental animal is the necessary amounts that measured matter is calculated on the basis, fills it in the gelatine capsule (1/2 ounce) of TORPAC corporate system.After the filling, capsule is put into the box of distinguishing by every animal, stored refrigerated before the administration.
(4) during route of administration and the administration
Between 9:00-12:30, force oral administration to fill the capsule of measured matter 1 time on the 1st to experimental animal.Experimental animal was gone on a hunger strike before administration 2 to 3 hours.
Be 11 during the administration.
(5) preparation of sample
Before the capsule administration-14 and (administration begins preceding the 2nd week and the 1st week) on the-7th, 4,8,12 about 10mL of venous blood collection from the beginning after the administration.Before the blood sampling experimental animal was gone on a hunger strike 18 hours in addition.
The blood that obtains is put into test tube, at room temperature place 30 minutes after 1 hour, use the serum that obtains after the centrifugalize (about 1600 * g, 10 minutes).
(6) test method
Make the NO that generates by nitric oxide synthetase (NOS), be converted into nitrate ion (NO rapidly
3 -) and nitrite ion (NO
2 -).Obtain NO with the HPLC method
3 -With NO
2 -Sum is as nitrogen oxide total concentration (NO in the blood
x).
Total cholesterol level uses enzyme assay, the HDL homogeneous assay method, and LDL uses the chemical modification enzyme assay, and ALP uses (Bessey-Lowry) algoscopy in Bei Xi-Lao.Use clinical chemistry automatic analysing apparatus (TBA-120FR, Toshiba's system) to measure.
(result of the test)
With the NO in the various blood that 2 weeks of administration are preceding and 1 week is preceding
xMeansigma methods converts and obtains simvastatin or Atorvastatin calcium as 100, and nitrogen oxide total concentration (NO in single agent of γ-Hi-Z or benfotiamine each dosage separately and the blood in the compounding ingredient
x).
In addition, with before administration 2 week and the meansigma methods of the lipid level in the various blood before 1 week as 100, lipid level in the convert single agent of obtaining simvastatin and γ-Hi-Z each dosage separately and the various blood in the compounding ingredient.
The result who obtains as shown in Table 1 and Table 2.Each numerical value all is 1 group 5 meansigma methods.
Table 1
Table 2
Table 3
Table 4
Table 5
By table 1 and table 2 as can be known, by simvastatin or atorvastatin, and γ-Hi-Z or benfotiamine and usefulness, show the effect that the synthetic of significant promotion blood vessel endothelium nitrogen oxide is arranged and/or keep or improve the blood level of blood vessel endothelium nitrogen oxide.
By table 3 and table 5 as can be known, by simvastatin and γ-Hi-Z and usefulness, show the effect that significant blood fat reducing level is arranged.
Industrial applicability
The pharmaceutical composition that the present invention contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamines class has the synthetic effect that promotes the blood vessel endothelium nitrogen oxide, keep or improve the effect of the blood level of blood vessel endothelium nitrogen oxide, with the effect that improves blood fat, therefore result from the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces as prevention or treatment, cause the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces, or result from the medicine of the high disease of serum lipid concentrations, for example, as prevention or treatment hypertension, hyperlipidemia, artery sclerosis, ischemic heart disease, in heart failure, thrombosis, pulmonary hypertension, the circulation system disease of restenosis or peripheral circulation disease etc., pulmonary hypertension, cerebral ischemia, cerebral infarction, the cranial vascular disease of brain circulatory diseases or senile dementia etc., the kidney disease in the urological system of ephrosis or impotence etc., diabetes or caused the medicine of the disease that NO generate to reduce by medicine.
Claims (27)
1. pharmaceutical composition, said composition contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class.
2. the described compositions of claim 1, wherein the HMG-CoA reductase inhibitor is to be selected from pravastatin, lovastatin, simvastatin, fluvastatin, upright a kind or the multiple reductase inhibitor that cuts down in his spit of fland, atorvastatin, Pitavastatin and the Rosuvastatin.
3. the described compositions of claim 1, wherein the HMG-CoA reductase inhibitor is a kind or the multiple reductase inhibitor that is selected from simvastatin or the atorvastatin.
4. any described compositions in the claim 1 to 3, wherein the thiamine class is a kind or the multiple thiamine class that is selected from thiamine, cetotiamine, neuvitan, commetamin, vitaberin, bisbentiamine, fursultiamine, prosultiamine, benfotiamine and/or their pharmaceutical salts.
5. any described compositions in the claim 1 to 3, wherein the thiamine class is a benfotiamine.
6. the blood level that any described compositions in the claim 1 to 5, said composition are used to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keep or improve the blood vessel endothelium nitrogen oxide.
7. any described compositions in the claim 1 to 5, said composition is used to improve blood fat.
8. the described compositions of claim 7, wherein the HMG-CoA reductase inhibitor is a simvastatin.
9. any described compositions in the claim 1 to 5, said composition are used to prevent or treat that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces the disease that causes.
10. any described compositions in the claim 1 to 5, said composition are used to prevent or treat the disease that causes that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces.
11. any described compositions in the claim 1 to 5, said composition are used to prevent or treat by blood circulation diseases, cerebrovascular disease, kidney diseases of urinary system, diabetes or medicine cause that NO generates the disease that reduces and produce.
12. any described compositions in the claim 1 to 5, said composition is used to prevent or treat the disease that hyperlipidemia concentration causes.
13. the described compositions of claim 12, it contains HMG-CoA reductase inhibitor and γ-essential composition of Hi-Z conduct.
14. any described compositions in the claim 1 to 3, said composition are used for prevention or treatment hyperlipemia or arteriosclerosis.
15. the associating of a HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, the blood level that it is used to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keeps or improve the blood vessel endothelium nitrogen oxide.
16. the described associating of claim 15 is wherein with HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same the time or with official hour administration respectively at interval.
17. the associating of a HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, this is united and is used to improve blood fat.
18. the described associating of claim 17 is wherein with HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same the time or with official hour administration respectively at interval.
19. HMG-CoA reductase inhibitor and γ-Hi-Z and/or the purposes of thiamine class in pharmaceutical compositions, said composition contains HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, the blood level that is used to promote the synthetic of blood vessel endothelium nitrogen oxide and/or keeps or improve the blood vessel endothelium nitrogen oxide.
20. the described purposes of claim 19, wherein said compositions are used to prevent or treat the disease that the blood vessel endothelium nitric oxide synthetase activities reduces and/or the blood level reduction of blood vessel endothelium nitrogen oxide causes.
21. the described purposes of claim 19, wherein said compositions are used to prevent or treat the disease that causes that the blood vessel endothelium nitric oxide synthetase activities reduces and/or blood vessel endothelium nitrogen oxide blood level reduces.
22. the described purposes of claim 19, wherein said compositions are used to prevent or treat by blood circulation diseases, cerebrovascular disease, kidney diseases of urinary system, diabetes or medicine cause that NO generates the disease that reduces and produce.
23. the described purposes of claim 19 is wherein with HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same the time or with official hour administration respectively at interval.
24. HMG-CoA reductase inhibitor and γ-Hi-Z and/or the purposes of thiamine class in pharmaceutical compositions, said composition contain HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine class, are used to improve blood fat.
25. the described purposes of claim 24, wherein said compositions are used to prevent or treat the disease that hyperlipidemia concentration causes.
26. the described purposes of claim 24, wherein said compositions are used for prevention or treatment hyperlipemia or arteriosclerosis.
27. the described purposes of claim 24 is wherein with HMG-CoA reductase inhibitor and γ-Hi-Z and/or thiamine roughly the same the time or with official hour administration respectively at interval.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002225979 | 2002-08-02 | ||
| JP225979/2002 | 2002-08-02 | ||
| JP260719/2002 | 2002-09-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1688314A CN1688314A (en) | 2005-10-26 |
| CN100415235C true CN100415235C (en) | 2008-09-03 |
Family
ID=35306248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038237059A Expired - Fee Related CN100415235C (en) | 2002-08-02 | 2003-08-01 | Medicinal composition containing an HMG-CoA reductase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100415235C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999006035A2 (en) * | 1997-07-31 | 1999-02-11 | Kos Pharmaceuticals, Inc. | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT |
| WO2002034261A1 (en) * | 2000-10-23 | 2002-05-02 | Sankyo Company, Limited | Compositions for improving lipids in blood |
-
2003
- 2003-08-01 CN CNB038237059A patent/CN100415235C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999006035A2 (en) * | 1997-07-31 | 1999-02-11 | Kos Pharmaceuticals, Inc. | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT |
| WO2002034261A1 (en) * | 2000-10-23 | 2002-05-02 | Sankyo Company, Limited | Compositions for improving lipids in blood |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1688314A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022090132A (en) | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid, and methods of using this pharmaceutical composition | |
| ES2232418T3 (en) | PHARMACOS COMBINATIONS, WHICH INCLUDE (E) -ACID 7- (4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- (METHYL-SULFONIL) -AMINO) -PIRIMIDIN-5-IL) (3R, 5S) -3,5-DIHYDROXIHEPT-6-ENOICO AND AN INHIBITOR, INDUCTOR OR SUBSTRATE FOR THE ISOENZYME 3A4 OF P450. | |
| US20060223811A1 (en) | Triglycerine depressant composition | |
| JP2010077162A (en) | Pharmaceutical composition for lowering homocysteine in blood | |
| CN100415235C (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
| JP2008189684A (en) | Blood lipid improving agent composition | |
| US20080070938A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | |
| JP4607436B2 (en) | Pharmaceutical composition containing an HMG-CoA reductase inhibitor | |
| US20050182036A1 (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
| US6916849B2 (en) | Compositions for improving lipid content in the blood | |
| JP2010150288A (en) | Medicinal composition containing statin and gamma-oryzanol | |
| JP4454985B2 (en) | Pharmaceutical composition for lowering blood lipids | |
| US20040023919A1 (en) | Blood lipid ameliorant composition | |
| JP4949661B2 (en) | Pharmaceutical composition containing HMG-CoA reductase inhibitor and glutathione | |
| JP4611622B2 (en) | Pharmaceutical composition for improving blood lipid or reducing blood homocysteine | |
| JP4896501B2 (en) | Pharmaceutical composition having blood free fatty acid lowering action | |
| EP2604258A1 (en) | Pharmaceutical composition comprising Losartan for treating or preventing statin based drug-induced muscle toxicity | |
| CN1688341A (en) | Medicinal composition for lowering blood lipid level | |
| JP4132773B2 (en) | Blood lipid improving agent composition | |
| JP4212271B2 (en) | Blood lipid improving agent composition | |
| JP4185280B2 (en) | Blood lipid improving agent composition | |
| JP4248780B2 (en) | Lipid peroxide reducing agent composition | |
| JPH1081633A (en) | Medicinal composition | |
| AU2013203070A1 (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| CN1929843A (en) | Composition for treating hyperlipoidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1077230 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1077230 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080903 Termination date: 20100801 |